PRIME Journal Vol. 11 Issue 3

news | NEWS | June/July 2021 9 uidepoint Qsight’s® data, which includes proprietary point-of-sale and survey data from hundreds of med spas and physician practices in the US, captured a surge of Millennial spending on non-surgical medical aesthetics treatments in March and April 2021. Non-surgical Medical Aesthetics treatment sales, particularly for neurotoxins, dermal fillers, and non-surgical skin tightening, reached unprecedented levels in March 2021 with strong growth continuing into April. Overall, Qsight aesthetics point-of-sale data shows sales growth up 27% in March and 14% in April when compared to 2019 (as a ‘pre-COVID’ baseline) with patients under age 40 growing 70% over the same period. Non-surgical skin tightening and neurotoxins procedures had the largest sales increase in March 2021, with 36% and 32% increases, respectively, over pre-COVID months. Non- surgical fat reduction sales benefited the least from the 2021 spike, with procedures down 4% over the same period in 2019. Dermal fillers sales also experienced strong sales growth of 16% compared to 2019. Qsight’s data also indicates that younger patients are contributing more to the 2021 aesthetic sales spike than patients over 60. In March and April 2021, versus per-COVID levels, spending by patients under 40 years of age increased by 70% over the same months in 2019 (with under 30 increasing by 112%). Conversely, sales by patients over 60 years of age decreased slightly (-6%). ‘Younger patients have been more likely to visit both med spas and physician offices during the pandemic and are spending in higher volumes. This seems to be a continuation of a longer-term trend of patients getting aesthetics procedures at younger ages,’ said Erik Haines, Managing Director of Guidepoint Qsight. ‘Based on commentary from our proprietary panel of medical aesthetics practitioners, the strong demand may be attributable to stimulus checks, an increase in disposable income, strong demand going into summer with less COVID restrictions, or a mixture of all the above.’ Guidepoint Qsight has been gathering data on the U.S. medical aesthetics industry since 2007 and recently expanded its market intelligence solutions to provide insight into near-real-time point-of-sale data from hundreds of med spa and physician practices across the U.S. Qsight’s proprietary aesthetics data offering is one of the only direct, timely, granular, and objective sources of information on this low-visibility, high-growth market. Around-upof news stories in theaestheticandanti-ageing medicine industry Thousands of women who were victims of the PIP breast implant scandal should receive compensation, a French appeal court has decided. Women involved in the case say they are elated and exhausted after 10 years of fighting for justice. The court also upheld an earlier judgement finding German safety body TUV Rheinland negligent. TUV said it had acted ‘diligently’, and that women must prove they had a PIP implant to be entitled to compensation. It awarded safety certificates for faulty breast implants made by French company Poly Implant Prothèse (PIP). The court decision could have far-reaching implications for thousands of other victims around the world. Jan Spivey, one of 540 British women involved in the case, was given PIP implants after she had a mastectomy due to breast cancer. After hearing the decision, she said she was ‘elated and exhausted’. ‘We’ve been in and out of court, and that’s been really difficult for women. We’ve got health issues and we’ve got lots of other responsibilities too—PIP has had an impact on the whole of our lives.’ Jan developed aching joints, pain and fatigue after having the implants, and once they were removed it was clear they had been leaking silicone into her body. NEWDATACAPTURESMILLENNIAL SPENDING SURGEONAESTHETIC TREATMENTS PIP IMPLANT VICTIMS ‘ELATED’ BY COMPENSATION WIN G DATA PROVIDED BY GUIDEPOINT QSIGHT REVEALS POPULAR TREATMENTS IN 2021 Younger patients visitedmed spas and physician officesmore during the pandemic and are spending in higher volumes.